Key result
Review evaluates cerebral embolic protection devices for reducing stroke and ischemic lesions during TAVI.
Why the study?
Stroke after TAVI is a devastating complication, and while several cerebral embolic protection devices have been developed to reduce peri-procedural ischaemic stroke and silent brain injury, their clinical benefit remains unknown.
Do Cerebral embolic protection devices (CEPD) reduce strokes or the onset of new ischaemic lesions in patients undergoing TAVI?
Do Cerebral embolic protection devices (CEPD) reduce strokes or the onset of new ischaemic lesions in patients undergoing TAVI?
This review examines the current evidence on whether cerebral embolic protection devices reduce the risk of stroke and new ischemic brain lesions during TAVI.
Stroke after transcatheter aortic valve (TAVI) is a devastating adverse event. The majority of these occur in the acute phase following TAVI where cerebral embolic events are frequent. Cerebral embolic protection devices (CEPD) have been developed to minimise the risk of peri-procedural ischaemic stroke during TAVI. CEPD have the potential to lower intraprocedural burden of new silent ischaemic brain injury. Several CEPD have been developed, but their clinical benefit remains unknown. Herein, we aimed to review the impact of the use of CEPD, in patients undergoing TAVI, on the reduction of strokes or the onset of new ischaemic lesions.
No takes yet. Share an insight, caveat, or question.
Deveci et al. (2021) conducted a review in Patients undergoing transcatheter aortic valve implantation (TAVI). Cerebral embolic protection devices (CEPD) was evaluated on Reduction of strokes or the onset of new ischaemic lesions. This review evaluates the impact of cerebral embolic protection devices on reducing strokes or new ischemic lesions during transcatheter aortic valve implantation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: